We observed a similar pattern of AR gain and loss between primary breast cancers and matched metastases as a previous study, which showed that AR was expressed ≥10% by SP107 in 82.9% of 164 primary breast tumours and 60.2% of 83 metastases, with a concordance rate of 60.6% between primary breast cancers and matched metastases [21]. Here, AR is linked to breast cancer.